A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Meptin swinghaler
Berotec
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled asthma; Stability was assessed during the past 14 days the patients remained in the same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had no acute exacerbations by investigator judgment;
- Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ; Positive result of Brocho-provocation test;
Exclusion Criteria:
- Hypersensitivity to β2-agonist or lactose;
- Hospitalization due to asthma during the previous 3 months;
- Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
- Oral or systemic corticosteroids in the previous 4 weeks;
- Inadequately controlled hyperthyroidism;
- Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory disease other than asthma(e.g. COPD), or any other disorder which may interfere wth the study evaluations or affect subject safety;
- Patients receive an investigational drug within 30 days prior to admission to the study;
- Patients with significant alcohol, drug or medication abuse as judged by the investigator;
- Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions);
- Subjects who are heavy smoker (more than 10 packs year) or who are smoking within previous 6 months.
Sites / Locations
- Chang Cung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Meptin swinghaler
Berotec
Arm Description
Outcomes
Primary Outcome Measures
The change of Forced Expiratory Volume in 1 second (FEV1) value
Secondary Outcome Measures
The change of Peak Expiratory Flow Rate (PEFR)
The change of Forced Vital Capacity (FVC)
Device acceptance
5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient
Full Information
NCT ID
NCT01095016
First Posted
March 15, 2010
Last Updated
January 15, 2013
Sponsor
Taiwan Otsuka Pharm. Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT01095016
Brief Title
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Official Title
An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
October 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taiwan Otsuka Pharm. Co., Ltd
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable asthma patients
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Meptin swinghaler
Arm Type
Experimental
Arm Title
Berotec
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Meptin swinghaler
Intervention Description
Dose: 10ug/puff, 2 puffs daily
Frequency: QD (total 20ug/day)
Treatment duration: 2 days
Intervention Type
Drug
Intervention Name(s)
Berotec
Intervention Description
Dose: 100ug/puff, 2 puffs daily
Frequency: QD (total 200ug/day)
Treatment duration: 2 days
Primary Outcome Measure Information:
Title
The change of Forced Expiratory Volume in 1 second (FEV1) value
Time Frame
12 months
Secondary Outcome Measure Information:
Title
The change of Peak Expiratory Flow Rate (PEFR)
Time Frame
12 months
Title
The change of Forced Vital Capacity (FVC)
Time Frame
12 months
Title
Device acceptance
Description
5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled asthma; Stability was assessed during the past 14 days the patients remained in the same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had no acute exacerbations by investigator judgment;
Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ; Positive result of Brocho-provocation test;
Exclusion Criteria:
Hypersensitivity to β2-agonist or lactose;
Hospitalization due to asthma during the previous 3 months;
Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
Oral or systemic corticosteroids in the previous 4 weeks;
Inadequately controlled hyperthyroidism;
Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory disease other than asthma(e.g. COPD), or any other disorder which may interfere wth the study evaluations or affect subject safety;
Patients receive an investigational drug within 30 days prior to admission to the study;
Patients with significant alcohol, drug or medication abuse as judged by the investigator;
Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions);
Subjects who are heavy smoker (more than 10 packs year) or who are smoking within previous 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yu-Hsiu Chung, MD
Organizational Affiliation
Chang Cung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Cung Memorial Hospital
City
Taipei
Country
Taiwan
12. IPD Sharing Statement
Learn more about this trial
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
We'll reach out to this number within 24 hrs